1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Jin F, Devesa SS, Chow WH, Zheng W, Ji BT,
Fraumeni JF Jr and Gao YT: Cancer incidence trends in urban
Shanghai, 1972–1994: An update. Int J Cancer. 83:435–440. 1999.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Dahlgren E, Friberg LG, Johansson S,
Lindström B, Odén A, Samsioe G and Janson PO: Endometrial
carcinoma; ovarian dysfunction-a risk factor in young women. Eur J
Obstet Gynecol Reprod Biol. 41:143–150. 1991. View Article : Google Scholar : PubMed/NCBI
|
4
|
Chen YL, Wang KL, Chen MY, Yu MH, Wu CH,
Ke YM, Chen YJ, Chang YY, Hsu KF and Yen MS: Risk factor analysis
of coexisting endometrial carcinoma in patients with endometrial
hyperplasia: A retrospective observational study of Taiwanese
Gynecologic Oncology Group. J Gynecol Oncol. 24:14–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner
M, Georgiev S, Fankhauser N, Noske A, Roessle M, Caduff R, Dellas
A, et al: p53 suppresses type II endometrial carcinomas in mice and
governs endometrial tumour aggressiveness in humans. EMBO Mol Med.
4:808–824. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Vale CL, Tierney J, Bull SJ and Symonds
PR: Chemotherapy for advanced, recurrent or metastatic endometrial
carcinoma. Cochrane Database Syst Rev. 15:CD0039152012.
|
7
|
Boll D, Verhoeven RH, van der Aa MA,
Pauwels P, Karim-Kos HE, Coebergh JW and van Doorn HC: Incidence
and survival trends of uncommon corpus uteri malignancies in the
Netherlands, 1989–2008. Int J Gynecol Cancer. 22:599–606. 2012.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Moreno-Moya JM, Vilella F and Simoón C:
MicroRNA: Key gene expression regulators. Fertil Steril.
101:1516–1523. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Dang X, Ma A, Yang L, Hu H, Zhu B, Shang
D, Chen T and Luo Y: MicroRNA-26a regulates tumorigenic properties
of EZH2 in human lung carcinoma cells. Cancer Genet. 205:113–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
13
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Vandenboom Ii TG, Li Y, Philip PA and
Sarkar FH: MicroRNA and cancer: Tiny molecules with major
implications. Curr Genomics. 9:97–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Segura MF, Hanniford D, Menendez S, Reavie
L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A,
Bogunovic D, et al: Aberrant miR-182 expression promotes melanoma
metastasis by repressing FOXO3 and microphthalmia-associated
transcription factor. Proc Natl Acad Sci USA. 106:pp. 1814–1819.
2009; View Article : Google Scholar : PubMed/NCBI
|
16
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Liang C, Zhang X, Wang HM, Liu XM, Zhang
XJ, Zheng B, Qian GR and Ma ZL: MicroRNA-18a-5p functions as an
oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis.
8:e27642017. View Article : Google Scholar : PubMed/NCBI
|
18
|
Yang X, Ruan H, Hu X, Cao A and Song L:
miR-381-3p suppresses the proliferation of oral squamous cell
carcinoma cells by directly targeting FGFR2. Am J Cancer Res.
7:913–922. 2017.PubMed/NCBI
|
19
|
Xia B, Li H, Yang S, Liu T and Lou G:
miR-381 inhibits epithelial ovarian cancer malignancy via YY1
suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhou S, Ye W, Ren J, Shao Q, Qi Y, Liang J
and Zhang M: MicroRNA-381 increases radiosensitivity in esophageal
squamous cell carcinoma. Am J Cancer Res. 5:267–277.
2014.PubMed/NCBI
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Shu S, Li X, Yang Y, Zhang Y, Li T, Liang
C and Wan J: Inhibitory effect of siRNA targeting IGF-1R on
endometrial carcinoma. Int Immunopharmacol. 11:244–249. 2011.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Pengchong H and Tao H: Expression of
IGF-1R, VEGF-C and D2-40 and their correlation with lymph node
metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol.
32:660–664. 2011.PubMed/NCBI
|
24
|
Chen G, Fang T, Huang Z, Qi Y, Du S, Di T,
Lei Z, Zhang X and Yan W: MicroRNA-133a inhibits osteosarcoma cells
proliferation and invasion via targeting IGF-1R. Cell Physiol
Biochem. 38:598–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
25
|
Ding WZ, Ni QF, Lu YT, Kong LL, Yu JJ, Tan
LW and Kong LB: MicroRNA-497 regulates cell proliferation in
hepatocellular carcinoma. Oncol Lett. 11:1081–1088. 2016.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Shimizu M, Shirakami Y, Sakai H, Tatebe H,
Nakagawa T, Hara Y, Weinstein IB and Moriwaki H: EGCG inhibits
activation of the insulin-like growth factor (IGF)/IGF-1 receptor
axis in human hepatocellular carcinoma cells. Cancer Lett.
262:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Hou XW, Sun X, Yu Y, Zhao HM, Yang ZJ,
Wang X and Cao XC: miR-361-5p suppresses lung cancer cell lines
progression by targeting FOXM1. Neoplasma. 64:526–534. 2017.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Li P, Wang X, Shan Q, Wu Y and Wang Z:
MicroRNA-130b promotes cell migration and invasion by inhibiting
peroxisome proliferator-activated receptor-γ in human glioma. Oncol
Lett. 13:2615–2622. 2017. View Article : Google Scholar : PubMed/NCBI
|
29
|
Rothschild SI, Tschan MP, Jaggi R, Fey MF,
Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is
deregulated in lung adenocarcinoma. J Thorac Oncol. 7:1069–1077.
2012. View Article : Google Scholar : PubMed/NCBI
|
30
|
He X, Wei Y, Wang Y, Liu L, Wang W and Li
N: miR-381 functions as a tumor suppressor in colorectal cancer by
targeting Twist1. Onco Targets Ther. 9:1231–1239. 2016.PubMed/NCBI
|
31
|
Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W
and Wang L: MicroRNA-381 inhibits the metastasis of gastric cancer
by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhang Q, Zhao S, Pang X and Chi B:
MicroRNA-381 suppresses cell growth and invasion by targeting the
liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep.
35:1831–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
33
|
Ming J, Zhou Y, Du J, Fan S, Pan B, Wang
Y, Fan L and Jiang J: miR-381 suppresses C/EBPα-dependent Cx43
expression in breast cancer cells. Biosci Rep. 35:e002662015.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Li Y, Zhao C, Yu Z, Chen J, She X, Li P,
Liu C, Zhang Y, Feng J, Fu H, et al: Low expression of miR-381 is a
favorite prognosis factor and enhances the chemosensitivity of
osteosarcoma. Oncotarget. 7:68585–68596. 2016.PubMed/NCBI
|
35
|
Chen B, Duan L, Yin G, Tan J and Jiang X:
miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer
cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J
Chemother. 25:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
36
|
Liang Y, Zhao Q, Fan L, Zhang Z, Tan B,
Liu Y and Li Y: Down-regulation of microRNA-381 promotes cell
proliferation and invasion in colon cancer through up-regulation of
LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
37
|
Xue Y, Xu W, Zhao W, Wang W, Zhang D and
Wu P: miR-381 inhibited breast cancer cells proliferation,
epithelial-to-mesenchymal transition and metastasis by targeting
CXCR4. Biomed Pharmacother. 86:426–433. 2017. View Article : Google Scholar : PubMed/NCBI
|
38
|
Wang Z, Yang J, Xu G, Wang W, Liu C, Yang
H, Yu Z, Lei Q, Xiao L, Xiong J, et al: Targeting miR-381-NEFL axis
sensitizes glioblastoma cells to temozolomide by regulating
stemness factors and multidrug resistance factors. Oncotarget.
6:3147–3164. 2015.PubMed/NCBI
|
39
|
Tang H, Wang Z, Liu Q, Liu X, Wu M and Li
G: Disturbing miR-182 and −381 inhibits BRD7 transcription and
glioma growth by directly targeting LRRC4. PLoS One. 9:e841462014.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Chen B and Liu B: miRNA-381 inhibits the
invasion of renal carcinoma and the underlying mechanisms. Zhong
Nan Da Xue Xue Bao Yi Xue Ban. 40:1053–1059. 2015.PubMed/NCBI
|
42
|
LeRoith D and Helman L: The new kid on the
block (ade) of the IGF-1 receptor. Cancer Cell. 5:201–202. 2004.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
44
|
E C, Li J, Shao D, Zhang D, Pan Y, Chen L
and Zhang X: The insulin-like growth factor-I receptor inhibitor
picropodophyllin-induced selective apoptosis of hepatocellular
carcinoma cell through a caspase-dependent mitochondrial pathway.
Oncol Res. 21:103–110. 2013.PubMed/NCBI
|
45
|
Yeo CD, Park KH, Park CK, Lee SH, Kim SJ,
Yoon HK, Lee YS, Lee EJ, Lee KY and Kim TJ: Expression of
insulin-like growth factor 1 receptor (IGF-1R) predicts poor
responses to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors in non-small cell lung cancer patients harboring
activating EGFR mutations. Lung Cancer. 87:311–317. 2015.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Ma Y, Cheng Q, Ren Z, Xu L, Zhao Y, Sun J,
Hu S and Xiao W: Induction of IGF-1R expression by EGR-1
facilitates the growth of prostate cancer cells. Cancer Lett.
317:150–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
47
|
Gryko M, Kisluk J, Cepowicz D, Zińczuk J,
Kamocki Z, Guzińska-Ustymowicz K, Pryczynicz A, Czyżewska J, Kemona
A and Kędra B: Expression of insulin-like growth factor receptor
type 1 correlate with lymphatic metastases in human gastric cancer.
Pol J Pathol. 65:135–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
48
|
Shan HB, Zhang R, Li Y, Xu GL, Luo GY, Gao
XY and Yang HL: Expression of IGF-1R in colorectal polyps and its
role in colorectal carcinogenesis. Technol Cancer Res Treat.
10:381–389. 2011. View Article : Google Scholar : PubMed/NCBI
|
49
|
Xie QX, Lin XC, Zhang MF, Han CX and Guo
YH: Expression of IGF-I and IGF-IR in bladder cancer. Ai Zheng.
23:707–709. 2004.(In Chinese). PubMed/NCBI
|
50
|
Werner H and LeRoith D: The role of the
insulin-like growth factor system in human cancer. Adv Cancer Res.
68:183–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
51
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
52
|
King H, Aleksic T, Haluska P and Macaulay
VM: Can we unlock the potential of IGF-1R inhibition in cancer
therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
53
|
Pavelić J, Radaković B and Pavelić K:
Insulin-like growth factor 2 and its receptors (IGF 1R and IGF
2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol
Oncol. 105:727–735. 2007. View Article : Google Scholar : PubMed/NCBI
|